FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2308583034> ?p ?o ?g. }

• W2308583034 endingPage "e0130277" @default.
• W2308583034 startingPage "e0130277" @default.
• W2308583034 abstract "Cancer prevention and therapy in HIV-1-infected patients will play an important role in future. The non-nucleoside reverse transcriptase inhibitors (NNRTI) Efavirenz and Nevirapine are cytotoxic against cancer cells in vitro. As other NNRTIs have not been studied so far, all clinically used NNRTIs were tested and the in vitro toxic concentrations were compared to drug levels in patients to predict possible anti-cancer effects in vivo.Cytotoxicity was studied by Annexin-V-APC/7AAD staining and flow cytometry in the pancreatic cancer cell lines BxPC-3 and Panc-1 and confirmed by colony formation assays. The 50% effective cytotoxic concentrations (EC50) were calculated and compared to the blood levels in our patients and published data.The in vitro EC50 of the different drugs in the BxPC-3 pancreatic cancer cells were: Efavirenz 31.5 μmol/l (= 9944 ng/ml), Nevirapine 239 μmol/l (= 63,786 ng/ml), Etravirine 89.0 μmol/l (= 38,740 ng/ml), Lersivirine 543 μmol/l (= 168,523 ng/ml), Delavirdine 171 μmol/l (= 78,072 ng/ml), Rilpivirine 24.4 μmol/l (= 8941 ng/ml). As Efavirenz and Rilpivirine had the highest cytotoxic potential and Nevirapine is frequently used in HIV-1 positive patients, the results of these three drugs were further studied in Panc-1 pancreatic cancer cells and confirmed with colony formation assays. 205 patient blood levels of Efavirenz, 127 of Rilpivirine and 31 of Nevirapine were analyzed. The mean blood level of Efavirenz was 3587 ng/ml (range 162-15,363 ng/ml), of Rilpivirine 144 ng/ml (range 0-572 ng/ml) and of Nevirapine 4955 ng/ml (range 1856-8697 ng/ml). Blood levels from our patients and from published data had comparable Efavirenz levels to the in vitro toxic EC50 in about 1 to 5% of all patients.All studied NNRTIs were toxic against cancer cells. A low percentage of patients taking Efavirenz reached in vitro cytotoxic blood levels. It can be speculated that in HIV-1 positive patients having high Efavirenz blood levels pancreatic cancer incidence might be reduced. Efavirenz might be a new option in the treatment of cancer." @default.
• W2308583034 created "2016-06-24" @default.
• W2308583034 creator A5027231637 @default.
• W2308583034 creator A5037590928 @default.
• W2308583034 creator A5050939441 @default.
• W2308583034 creator A5053999765 @default.
• W2308583034 creator A5060178386 @default.
• W2308583034 creator A5079719869 @default.
• W2308583034 creator A5079727934 @default.
• W2308583034 creator A5086812053 @default.
• W2308583034 creator A5016579897 @default.
• W2308583034 date "2015-06-18" @default.
• W2308583034 modified "2023-10-02" @default.
• W2308583034 title "Efavirenz Has the Highest Anti-Proliferative Effect of Non-Nucleoside Reverse Transcriptase Inhibitors against Pancreatic Cancer Cells" @default.
• W2308583034 cites W125106425 @default.
• W2308583034 cites W1495541129 @default.
• W2308583034 cites W1963944716 @default.
• W2308583034 cites W1968307105 @default.
• W2308583034 cites W1972471794 @default.
• W2308583034 cites W1973438686 @default.
• W2308583034 cites W1982644994 @default.
• W2308583034 cites W1986842451 @default.
• W2308583034 cites W1987240689 @default.
• W2308583034 cites W1993247709 @default.
• W2308583034 cites W1994155138 @default.
• W2308583034 cites W2002118607 @default.
• W2308583034 cites W2002933376 @default.
• W2308583034 cites W2004022724 @default.
• W2308583034 cites W2005426394 @default.
• W2308583034 cites W2008423758 @default.
• W2308583034 cites W2008456450 @default.
• W2308583034 cites W2010480563 @default.
• W2308583034 cites W2042297223 @default.
• W2308583034 cites W2050280124 @default.
• W2308583034 cites W2060218003 @default.
• W2308583034 cites W2063375793 @default.
• W2308583034 cites W2069078286 @default.
• W2308583034 cites W2072661867 @default.
• W2308583034 cites W2073074889 @default.
• W2308583034 cites W2076201678 @default.
• W2308583034 cites W2080401134 @default.
• W2308583034 cites W2085167526 @default.
• W2308583034 cites W2086616638 @default.
• W2308583034 cites W2095912264 @default.
• W2308583034 cites W2099746597 @default.
• W2308583034 cites W2101257503 @default.
• W2308583034 cites W2101940803 @default.
• W2308583034 cites W2102467710 @default.
• W2308583034 cites W2106737113 @default.
• W2308583034 cites W2113154926 @default.
• W2308583034 cites W2117854357 @default.
• W2308583034 cites W2120602370 @default.
• W2308583034 cites W2127291942 @default.
• W2308583034 cites W2127621626 @default.
• W2308583034 cites W2145785697 @default.
• W2308583034 cites W2149133771 @default.
• W2308583034 cites W2153253704 @default.
• W2308583034 cites W2157488233 @default.
• W2308583034 cites W2162697298 @default.
• W2308583034 cites W2168992025 @default.
• W2308583034 cites W2170136961 @default.
• W2308583034 cites W2413673485 @default.
• W2308583034 cites W2414814188 @default.
• W2308583034 cites W4041946 @default.
• W2308583034 cites W4240479615 @default.
• W2308583034 doi "https://doi.org/10.1371/journal.pone.0130277" @default.
• W2308583034 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4473268" @default.
• W2308583034 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26086472" @default.
• W2308583034 hasPublicationYear "2015" @default.
• W2308583034 type Work @default.
• W2308583034 sameAs 2308583034 @default.
• W2308583034 citedByCount "39" @default.
• W2308583034 countsByYear W23085830342015 @default.
• W2308583034 countsByYear W23085830342016 @default.
• W2308583034 countsByYear W23085830342017 @default.
• W2308583034 countsByYear W23085830342018 @default.
• W2308583034 countsByYear W23085830342019 @default.
• W2308583034 countsByYear W23085830342020 @default.
• W2308583034 countsByYear W23085830342021 @default.
• W2308583034 countsByYear W23085830342022 @default.
• W2308583034 countsByYear W23085830342023 @default.
• W2308583034 crossrefType "journal-article" @default.
• W2308583034 hasAuthorship W2308583034A5016579897 @default.
• W2308583034 hasAuthorship W2308583034A5027231637 @default.
• W2308583034 hasAuthorship W2308583034A5037590928 @default.
• W2308583034 hasAuthorship W2308583034A5050939441 @default.
• W2308583034 hasAuthorship W2308583034A5053999765 @default.
• W2308583034 hasAuthorship W2308583034A5060178386 @default.
• W2308583034 hasAuthorship W2308583034A5079719869 @default.
• W2308583034 hasAuthorship W2308583034A5079727934 @default.
• W2308583034 hasAuthorship W2308583034A5086812053 @default.
• W2308583034 hasBestOaLocation W23085830341 @default.
• W2308583034 hasConcept C121608353 @default.
• W2308583034 hasConcept C126322002 @default.
• W2308583034 hasConcept C142462285 @default.
• W2308583034 hasConcept C154317977 @default.
• W2308583034 hasConcept C159047783 @default.
• W2308583034 hasConcept C185592680 @default.

• next